Tiny Val­lon’s at­tempt at break­ing in­to the big Adder­all mar­ket just went up in smoke — and so did its stock

Last month, Val­lon Phar­ma­ceu­ti­cals tout­ed the hope that it could tap in­to the Adder­all mar­ket with an AD­HD med that de­ters peo­ple from drug abuse. That now looks like a pipe dream, and the rest of the biotech’s pipeline could be up in the air with the drug’s Phase III flop.

It’s not a high note for Val­lon, which suf­fered a 71% share price bat­ter­ing Mon­day morn­ing fol­low­ing news of the fail­ure. Mark it as a quick fall for the Philly biotech, which land­ed on Nas­daq just 13 months ago.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER